Real Chemistry Acquires Avant Healthcare

Real Chemistry Acquires Greater Than One

July 22, 2025

Marketing & Advertising

Real Chemistry has acquired Greater Than One, an award-winning healthcare-first media, technology and omnichannel strategy agency. The deal brings Greater Than One's proprietary media planning and engagement tools into Real Chemistry's AI-driven healthcare marketing platform to expand capability and performance for pharma and biotech clients; terms were not disclosed.

Real Chemistry Acquires conversationHEALTH

April 5, 2022

Healthcare Services

Real Chemistry, a San Francisco-based health innovation company, has acquired conversationHEALTH, a HIPAA-compliant conversational AI SaaS platform for the health care and life sciences industry. The acquisition expands Real Chemistry's Data and Artificial Intelligence Solutions capabilities by adding conversational AI, medically-trained NLU and intelligent agents for scientific communications, medical affairs, clinical trials and commercial operations.

Real Chemistry Acquires Spring & Bond

October 15, 2025

Marketing & Advertising

Real Chemistry has acquired Spring & Bond, a New York–based digital media agency focused on omnichannel, data-driven media for the healthcare sector. The deal strengthens Real Chemistry's media and omnichannel capabilities; Spring & Bond's founder Elizabeth Beringer will continue to lead the team reporting to Kevin Johnson.

Real Chemistry Acquires TI Health and Integrates It into Swoop

March 1, 2023

Data & Analytics

Real Chemistry has acquired TI Health, a data-driven HCP engagement and predictive analytics company, and will integrate TI Health into Swoop to create a unified HCP and DTC system of engagement for healthcare marketers. TI Health, previously a portfolio company of Capital Dynamics, Star Mountain Capital, and Halyard Capital, will bring its Affiniti platform and HCP targeting capabilities to Swoop’s privacy-safe patient audiences to enable coordinated omnichannel campaigns.

X-Chem Acquires IntelliSyn and AviSyn to Expand Drug Discovery Services

January 26, 2021

Biotechnology

X-Chem, a portfolio company of GHO Capital, has acquired Montreal-based IntelliSyn and its US-based sister company AviSyn to extend its drug discovery offering into medicinal chemistry, custom synthesis and scale-up process chemistry. The deal integrates downstream hit validation and lead optimisation capabilities into X-Chem’s DNA-Encoded Library (DEL) platform, enabling a streamlined screen-to-lead service for pharma and biotech clients; financial terms were not disclosed.

Datavant Acquires Aetion

July 13, 2025

Healthcare Services

Datavant has completed its acquisition of Aetion, bringing the real-world evidence (RWE) platform into Datavant’s Life Sciences business to create an end-to-end data feasibility and analysis offering. The deal combines Datavant’s data connectivity network with Aetion’s RWE analytics to expand capabilities for biopharma, device makers, payers, and regulators.